Literature DB >> 20582941

Imatinib mesylate for children with dermatofibrosarcoma protuberans (DFSP).

Saskia L M Gooskens1, Arnold P Oranje, Leon N A van Adrichem, Flora B de Waard-van der Spek, Jan C den Hollander, Cees P van de Ven, Marry M van den Heuvel-Eibrink.   

Abstract

Dermatofibrosarcoma protuberans (DFSP) is a rare malignant soft tissue tumor in children. DFSP is characterized by a specific fusion of the platelet-derived growth factor beta (PDGFbeta) with the collagen type 1alpha1 (COL1alpha1) gene which renders these tumors responsive to targeted therapy with tyrosine kinase inhibitors, such as imatinib mesylate, as is reported in adults. In the current report, we describe the first small pediatric DFSP series, in which response to imatinib mesylate contributed to successful treatment outcome. (c) 2010 Wiley-Liss, Inc.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20582941     DOI： 10.1002/pbc.22494

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN： 1545-5009            Impact factor:   3.167


  12 in total

1.  Dermatofibrosarcoma protuberans: Our experience of 59 cases.

Authors:  Alessio Stivala; Giuseppe A G Lombardo; Gianluca Pompili; Maria Stella Tarico; Filippo Fraggetta; Rosario Emanuele Perrotta
Journal:  Oncol Lett       Date:  2012-08-30       Impact factor: 2.967

2.  Status report on the management of dermatofibrosarcoma protuberans: is there a viable role for the use of imatinib mesylate? In which cases may it be therapeutically helpful and in which cases not?

Authors:  Grace K Kim
Journal:  J Clin Aesthet Dermatol       Date:  2011-03

Review 3.  Dermatofibrosarcoma Protuberans in Children.

Authors:  Aseel Sleiwah; Thomas C Wright; Thomas Chapman; Adam Dangoor; Francesca Maggiani; Rachel Clancy
Journal:  Curr Treat Options Oncol       Date:  2022-04-08

4.  Dermatofibrosarcoma protuberans in a 10-year-old child.

Authors:  Uwe Wollina
Journal:  J Dermatol Case Rep       Date:  2013-12-30

Review 5.  Advances in therapy for pediatric sarcomas.

Authors:  Aaron Weiss; Jonathan Gill; John Goldberg; Joanne Lagmay; Holly Spraker-Perlman; Rajkumar Venkatramani; Damon Reed
Journal:  Curr Oncol Rep       Date:  2014       Impact factor: 5.075

Review 6.  New advances in the molecular classification of pediatric mesenchymal tumors.

Authors:  Albert J H Suurmeijer; Yu-Chien Kao; Cristina R Antonescu
Journal:  Genes Chromosomes Cancer       Date:  2018-10-11       Impact factor: 5.006

7.  Cambogin is preferentially cytotoxic to cells expressing PDGFR.

Authors:  Ze Tian; Jie Shen; Fengfei Wang; Peigen Xiao; Junshan Yang; Hetian Lei; Andrius Kazlauskas; Isaac S Kohane; Erxi Wu
Journal:  PLoS One       Date:  2011-06-21       Impact factor: 3.240

8.  Nilotinib counteracts P-glycoprotein-mediated multidrug resistance and synergizes the antitumoral effect of doxorubicin in soft tissue sarcomas.

Authors:  Victor Hugo Villar; Oliver Vögler; Jordi Martínez-Serra; Rafael Ramos; Silvia Calabuig-Fariñas; Antonio Gutiérrez; Francisca Barceló; Javier Martín-Broto; Regina Alemany
Journal:  PLoS One       Date:  2012-05-25       Impact factor: 3.240

9.  Neoadjuvant treatment of Dermatofibrosarcoma Protuberans of pancreas with Imatinib: case report and systematic review of literature.

Authors:  Mashaal Dhir; David G Crockett; Todd M Stevens; Peter T Silberstein; William J Hunter; Jason M Foster
Journal:  Clin Sarcoma Res       Date:  2014-08-06

10.  Surgical Treatment of Dermatofibrosarcoma Protuberans Using a Reversed Adipofascial Sural Flap - Case Report.

Authors:  Bogdan Stancu; Ion Aurel Mironiuc; Maria Crisan; Mihaela Mera
Journal:  Clujul Med       Date:  2014-11-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.